<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383406</url>
  </required_header>
  <id_info>
    <org_study_id>AsanMC_LMP2017-001</org_study_id>
    <nct_id>NCT03383406</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma</brief_title>
  <acronym>IVAM</acronym>
  <official_title>A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II trial of ifosfamide, etoposide, cytarabine, and methotrexate (IVAM) chemotherapy&#xD;
      for refractory or relapsed diffuse large B cell lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diffuse Large B-Cell lymphoma is currently used as a standard treatment, with a combination&#xD;
      of chemotherapy (R-CHOP), which includes Rituximab. However, the survival rate is very poor&#xD;
      if the primary treatment is refractory or relapsed within a year or less. The duration of&#xD;
      these patients ' lives is around one year and the five-year survival rate is 15-20 %. Thus, a&#xD;
      new treatment strategy is needed to improve the survival of the patient with DLBCL, which are&#xD;
      either refractory and relapsed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>2 to 3 weeks after completion of the 2nd cycle of treatment (each cycle is 28 days)</time_frame>
    <description>CT, PET-CT(positron emission computed tomography )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess response rate</measure>
    <time_frame>4 to 5 weeks after completion of the 4th cycle of treatment(each cycle is 28 days)</time_frame>
    <description>CT, PET-CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess response rate</measure>
    <time_frame>6 to 8 weeks after completion of the 6th cycle of treatment(each cycle is 28 days)</time_frame>
    <description>CT, PET-CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess response rate</measure>
    <time_frame>After completion of the treatment, up to 24weeks</time_frame>
    <description>CT, PET-CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess response rate</measure>
    <time_frame>After 1year completion of the treatment up to 1year</time_frame>
    <description>CT, PET-CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess response rate</measure>
    <time_frame>Afer 2years completion of the treatment up to 3years</time_frame>
    <description>CT, PET-CT</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess overall survival</measure>
    <time_frame>The time from the 1st day of treatment to death of any cause or the date of last follow-up, assessed up to 66 months</time_frame>
    <description>CT, PET-CT</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>I Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy</intervention_name>
    <description>Every cycle(4weeks)&#xD;
Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1~Day3 by Intravenous infusion.</description>
    <arm_group_label>I Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM)</arm_group_label>
    <other_name>IVAM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Histologically confirmed adult patients diagnosed with DLBCL refractory or relapsed.&#xD;
&#xD;
          -  Large scale B cell lymphoma not received ASCT(autologous stem-cell transplantation )&#xD;
             after primary chemotherapy&#xD;
&#xD;
          -  At least one measurable lesion&#xD;
&#xD;
               -  ≥1 cm in greatest transverse diameter by spiral CT&#xD;
&#xD;
               -  ≥2 cm in greatest transverse diameter by conventional CT&#xD;
&#xD;
               -  ≥1 cm in visible skin lesion&#xD;
&#xD;
               -  ≥2 cm in digital exploration&#xD;
&#xD;
          -  Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2.&#xD;
&#xD;
          -  Age 19~59yrs&#xD;
&#xD;
          -  MUGA(multiple gated acquisition scan ): Non-Clinical significant and 2D-Echo( Cardiac&#xD;
             Index ≥ 50 % )&#xD;
&#xD;
          -  Adequate renal function: serum creatinine level &lt; 2.0 mg/dL(177μmol/L) Adequate liver&#xD;
             functions: Transaminase (AST/ALT) &lt; 3 X upper limit of normal value (or &lt; 5 x ULN in&#xD;
             the presence of DLBCL involvement of the liver), bilirubin &lt; 2 X upper normal value&#xD;
             (or &lt; 5 x upper limit of normal in the presence of DLBCL involvement of the liver)&#xD;
&#xD;
          -  Adequate hematological function: hemoglobin ≥ 9.0 g/dL absolute neutrophil count (ANC)&#xD;
             ≥ 1,500/μL and platelet count ≥ 75,000/μL,&#xD;
&#xD;
          -  A negative serum or urine pregnancy test prior to treatment must be available both for&#xD;
             pre menopausal women and for women who are &lt; 1 years after the onset of menopause.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-treatment for ASCT&#xD;
&#xD;
          -  Central nervous system (CNS) involvement by lymphoma&#xD;
&#xD;
          -  Prior history of malignancies other than lymphoma (except for treated Non Melanoma&#xD;
             Skin Cancer, early gastric cancer or carcinoma in situ of the cervix or breast or&#xD;
             untreated prostatic cancer without any plan for a treatment) unless the patient has&#xD;
             been free of the disease for ≥ 5 years&#xD;
&#xD;
          -  Pregnant or lactating woman, Childbearing potential not employing adequate&#xD;
             contraception&#xD;
&#xD;
          -  Active uncontrolled infections(Bacterial, Viral, Fungus)&#xD;
&#xD;
          -  Other serious illness or medical conditions&#xD;
&#xD;
          -  Other experimental drug under investigation, or concomitant chemotherapy, hormonal&#xD;
             therapy, or immunotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Cheolwon Suh</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

